Business Wire (Thu, 8:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,319 people get NPSP articles and Market Currents by email alert.
Get email alerts on NPSP »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (May 9, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 26, 2013)
-
Business Wire (Apr 22, 2013)
-
-
-
-
-
-
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 21, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
Current Prime Pharma Entries In Anticipation Of Prime Time ExitsChemistfrog • Tue, Nov 6, 2012 -
-
What Moves Biotech Stocks? Ed Arce Has AnswersLife Sciences Report • Thu, Oct 18, 2012 -
-
-
-
-
-
NPS Pharmaceuticals' CEO Discusses Gattex Update (Transcript)Wed, Oct 17, 2012 • 1 Comment
-
NPS Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptThu, May 6, 2010
-
NPS Pharmaceuticals Inc. Q4 2008 Earnings Call TranscriptFri, Mar 13, 2009
-
NPS Pharmaceuticals, Inc. Q2 2008 Earnings Call TranscriptTue, Sep 2, 2008
-
Business Wire (May 9, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 26, 2013)
-
Business Wire (Apr 22, 2013)
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 21, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 13, 2013)
-
Business Wire (Feb 5, 2013)
-
at CNBC.com (Jan 7, 2013)
-
Business Wire (Jan 3, 2013)
-
Business Wire (Dec 21, 2012)
NPSP vs. ETF Alternatives
Company Description
Currently, there's no company description for NPSP.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 1, 3:24 PM A number of biotechs are sharply lower amid rumors of a sizable Bio-fund going out of business and liquidating its positions. It's Ayer Capital Management according to sources, reports Adam Feuerstein. (PCYC -5.6%), (CLDX -4.9%), (NPSP -3.1%), (HALO -3.8%). 6 Comments [Healthcare, On the Move]
- Wednesday, April 24, 9:24 AM Oppenheimer initiates NPS Pharmaceuticals (NPSP) at Outperform with a price target of $18. "There are no direct competitors for Gattex and Natpara," writes analyst Boris Peaker, adding that investors shouldn't be wary of "owning a launch name" in this case because the company's "first-in-class compounds [should] generate substantial commercial traction given their therapeutic benefits." Shares +1.81% premarket. Comment! [On the Move, Healthcare]
-
Tuesday, March 19, 1:00 PM
Midday top 10 gainers: EFUT +53%. ATOS +29%. GST +20%. KYTH +14%. DWCH +10%. NPSP +9%. SHIP +9%. CSTE +8%. OPXA +8%. LTRX +8%.
Midday top 10 losers: AFFY -64%. MTSL -33%. HNR -33%. WSCI -23%. WAC -19%. INTX -19%. STSI -17%. TWER -14%. CLWT -13%. GMXR -13%. Comment! [On the Move] -
Tuesday, March 19, 9:10 AM
Premarket gainers: NPSP +10%. SKUL +7%. ABC +6%. ACAD +5%.
Losers: AFFY -59%. HNR -46%. MTSL -30%. STSI -11%. CAH -8%. DSW -7%. HPT -6%. Comment! [On the Move] -
Friday, October 12, 2012, 12:45 PM
Midday top 10 gainers: NINE +62%. CRMB +16%. NPSP +15%. AEGR +13%. GLUU +12%. LXRX +11%. TSON +11%. BIOF +10%. EMAN +10%. BSDM +9%.
Top 10 Losers: AEZS -24%. OCZ -17%. TZOO -14%. PURE -11%. INVE -11%. AMD -10%. LQDT -10%. CCCL -9%. INFY -9%. Comment! [On the Move] - Friday, October 12, 2012, 12:37 PM NPS Pharmaceuticals (NPSP 14.3%) pops today after it says the FDA has released the briefing documents ahead of its October 16 Advisory Committee meeting for NPSP's experimental drug Gattex, which is being developed for the treatment of adults with short bowel syndrome. The overall comments appear to be positive, with no serious safety issues raised. The advisers also said access to the drug should not be restricted, nor will it require additional elements to assure it's safe use. Comment! [Healthcare, On the Move]
-
Friday, October 12, 2012, 9:10 AM
Premarket gainers: NPSP +11%. CTIC +9%. STM +8%.
Losers: AEZS -24%. AMD -11%. INFY -7%. 1 Comment [On the Move] -
Friday, June 22, 2012, 9:10 AM
Premarket gainers: HNR +82%. ALXA +19%. NPSP +9%.
Losers: PLX -12%. R -10%. 2 Comments [On the Move] - Friday, June 22, 2012, 9:03 AM NPS Pharmaceuticals (NPSP) +8.3% premarket after the company and drug partner Takeda (TKPHF.PK) say a European panel recommended their Revestive drug receive marketing approval as a once-daily treatment for adults with short bowel syndrome. Comment! [Healthcare, On the Move]
- Tuesday, January 31, 2012, 9:46 AM NPS Pharmaceuticals (NPSP +1.8%) trades higher after the FDA accepts its Gattex drug application for review. Slicing through the firm's statement a bit - it appears that it didn't land a coveted "priority" review from the FDA. Comment! [Healthcare, On the Move]
- Friday, December 2, 2011, 12:10 PM NPS Pharmaceuticals (NPSP +5.4%) clocks a gain a day after announcing it completed its submission to the FDA for its experimental Gattex drug - a hopeful sign which follows the firm reporting "adverse events" in October with trials. Comment! [Healthcare, On the Move]
- Monday, November 7, 2011, 1:44 PM NPS Pharmaceuticals (NPSP -3.7%) gives back all its premarket gains and more, despite the postive Phase 3 results for its hypoparathyroid treatment earlier today. The company has been on a steady downtrend for most of this year, losing nearly 50% since hitting a 52-week high in May. 1 Comment [Healthcare, On the Move]
- Monday, November 7, 2011, 8:52 AM Shares of NPS Pharmaceuticals (NPSP), up 8.8% premarket, gain back some ground lost over the last week after the company announces positive top-line results for a trial of its endocrine disorder treatment. Comment! [On the Move, Healthcare]
- Monday, October 31, 2011, 11:18 AM NPS Pharmaceuticals (NPSP -34.9%) sinks after the company reports "adverse events" in a trial of its experimental short bowel syndrome therapy - Gattex - including two patients dying from cancer. Comment! [On the Move, Healthcare]
- Tuesday, August 2, 2011, 6:05 PM NPS Pharmaceuticals (NPSP) terminates and replaces a prior collaborative research agreement with GlaxoSmithKline (GSK) dating back to 1993. The new agreement will assign two new compounds for study and expand the company's field of research on other drugs. NPSP +7.9%, [[GSK] -0.9% AH. Comment! [Healthcare, On the Move]
-
Codespeed
$NBIX $NPSP technical charts, strong catalysts, good returns: http://seekingalpha.com/a/syx1 - View all 0 replies
-
- View all 1 replies
-
-
- View all 1 replies
-
whitehead1: I missed and missed and missed. Please go under 5 for one more time please
-
smokeyRose
Should i sell Should i sell My $JAZZ and $NPSP and Buy $SRPT ????? What to do What To Do What To Do - View all 2 replies
-
-
-
- View all 0 replies
-
Corey Papcun
NPSP was scheduled to report 3rd quarter earnings today at 4:30. Are they holding off due to the election? - View all 1 replies
-
-
freefdawatchlist
http://stks.co/mCem Premarket loser $FTNT (-16%), $APOL (-12%), $ISRG (-5%), $NPSP (-4%), $INTC(-4%) - View all 0 replies
-
- View all 0 replies
-
Michael Bryant
"FDA staff says NPS Pharma's (NPSP) bowel drug needs no safety restrictions." Drug may be nearing approval. http://bit.ly/SWHPDY - View all 0 replies
-
- View all 1 replies
-
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 1 replies
-
whitehead1: I missed and missed and missed. Please go under 5 for one more time please
-
smokeyRose
Should i sell Should i sell My $JAZZ and $NPSP and Buy $SRPT ????? What to do What To Do What To Do - View all 2 replies
-
-
-
Corey Papcun
NPSP was scheduled to report 3rd quarter earnings today at 4:30. Are they holding off due to the election? - View all 1 replies
-
-
- View all 1 replies
-